Psagot Value Holdings Ltd. Israel raised its holdings in shares of Pfizer Inc. (NYSE: PFE – Get Rating) by 194.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,197 shares of the biopharmaceutical company stock after acquiring an additional 58,272 shares during the period. Psagot Value Holdings Ltd. Israel’s holdings in Pfizer were worth $ 1,287,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Econ Financial Services Corp purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $ 31,000. PYA Waltman Capital LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $ 31,000. Rinkey Investments purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $ 32,000. TFO TDC LLC boosted its stake in shares of Pfizer by 126.9% during the fourth quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company stock valued at $ 37,000 after purchasing an additional 373 shares during the period. Finally, Bivin & Associates Inc. purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $ 37,000. Institutional investors and hedge funds own 66.50% of the company stock.
Shares of NYSE: PFE opened at $ 46.53 on Friday. The stock has a market capitalization of $ 261.08 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 0.58 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The stock’s 50-day simple moving average is $ 50.90 and its two-hundred day simple moving average is $ 52.33. Pfizer Inc. has a 52-week low of $ 38.70 and a 52-week high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $ 1.66 by ($ 0.04). The firm had revenue of $ 25.66 billion during the quarter, compared to analysts’ expectations of $ 24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company revenue for the quarter was up 76.8% on a year-over-year basis. During the same period in the previous year, the business posted $ 0.93 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were given a dividend of $ 0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $ 1.60 dividend on an annualized basis and a dividend yield of 3.44%. Pfizer’s payout ratio is currently 36.70%.
In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $ 50.00, for a total value of $ 1,645,400.00. Following the transaction, the executive vice president now directly owns 38,146 shares of the company stock, valued at approximately $ 1,907,300. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at $ 760,732. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,126 shares of company stock worth $ 2,075,003. Insiders own 0.05% of the company stock.
A number of analysts recently commented on the company. Citigroup raised their price target on Pfizer from $ 46.00 to $ 57.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 5th. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Morgan Stanley assumed coverage on Pfizer in a research note on Wednesday, April 6th. They issued an “equal weight” rating and a $ 55.00 price target for the company. SVB Leerink assumed coverage on Pfizer in a research note on Monday, May 23rd. They issued a “market perform” rating and a $ 55.00 price target for the company. Finally, The Goldman Sachs Group set a $ 51.00 price target on Pfizer in a research note on Wednesday, May 25th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Buy” and an average price target of $ 57.26.
Pfizer Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Featured Articles:
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.
.